News

Zacks Investment Research on MSN1d
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer
AstraZeneca AZN announced that the FDA has expanded the label of its cancer drug Datroway for a second indication — non-small ...
Medical Dialogues4h
AstraZeneca Datroway gets USFDA accelerated nod for previously treated advanced EGFR-mutated non-small cell lung cancer
Cambridge: AstraZeneca has announced that Datroway (datopotamab deruxtecan or Dato-DXd) has received accelerated approval ...
AstraZeneca (LSE:AZN) Gains FDA Approval For Datroway In Treating Advanced Lung Cancer
AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non ...
Fierce Pharma1d
AZ, Daiichi's Datroway scores its 2nd FDA approval—this time in lung cancer subset
The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal ...
PharmExec1d
FDA Grants Accelerated Approval to AstraZeneca, Daiichi Sankyo’s Datroway for Previously Treated, Locally Advanced or Metastatic EGFR-Mutated NSCLC
Approval was based on results from the Phase II TROPION-Lung05 trial, which showed that Datroway demonstrated a strong ...
GlobalData on MSN2d
FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for NSCLC
The US Food and Drug Administration (FDA) has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for ...
FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...
CURE2d
FDA Approves Datroway for EGFR-Mutated Advanced Lung Cancer
Datroway received accelerated FDA approval for adults with EGFR+ advanced non-small cell lung cancer after EGFR-targeted and ...
AstraZeneca and Daiichi Sankyo Treatment Wins First of Its Kind FDA Blessing to Treat Lung Cancer
Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its ...
Becker's Hospital Review1d
FDA approves treatment for non-small cell lung cancer
The FDA has granted accelerated approval to datopotamab deruxtecan (Datroway) for adults with locally advanced or metastatic non-small cell lung cancer that carries an EGFR mutation and has progressed ...
Nasdaq1d
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer
Datroway was granted breakthrough therapy designation by the FDA in this indication last December. AZN Stock Performance Year to date, AstraZeneca’s shares have gained 8% against the industry ...